Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · IEX Real-Time Price · USD
7.85
+0.20 (2.61%)
At close: May 31, 2024, 4:00 PM
7.75
-0.10 (-1.27%)
After-hours: May 31, 2024, 6:53 PM EDT

Fulcrum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2017
Revenue
2.816.3419.168.820
Upgrade
Revenue Growth (YoY)
-55.77%-66.90%117.19%--
Upgrade
Gross Profit
2.816.3419.168.820
Upgrade
Selling, General & Admin
41.6741.6930.5221.3913.15
Upgrade
Research & Development
71.876.7869.759.0471.07
Upgrade
Other Operating Expenses
00.43000
Upgrade
Operating Expenses
113.47118.9100.2280.4384.22
Upgrade
Operating Income
-110.66-112.56-81.05-71.61-84.22
Upgrade
Other Expense / Income
-13.33-2.69-0.21-0.79-1.54
Upgrade
Pretax Income
-97.34-109.87-80.85-70.82-82.68
Upgrade
Net Income
-97.34-109.87-80.85-70.82-82.68
Upgrade
Preferred Dividends
00007.13
Upgrade
Net Income Common
-97.34-109.87-80.85-70.82-89.81
Upgrade
Shares Outstanding (Basic)
6145352511
Upgrade
Shares Outstanding (Diluted)
6145352511
Upgrade
Shares Change
36.27%27.23%39.47%129.53%778.76%
Upgrade
EPS (Basic)
-1.59-2.44-2.29-2.79-8.13
Upgrade
EPS (Diluted)
-1.59-2.44-2.29-2.79-8.13
Upgrade
Free Cash Flow
-91.47-99.01-80.19-55-40.34
Upgrade
Free Cash Flow Per Share
-1.49-2.20-2.27-2.17-3.65
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%-
Upgrade
Operating Margin
-3945.24%-1774.85%-422.97%-811.64%-
Upgrade
Profit Margin
-3470.05%-1732.43%-421.89%-802.66%-
Upgrade
Free Cash Flow Margin
-3261.07%-1561.23%-418.47%-623.34%-
Upgrade
EBITDA
-95.16-107.46-78.33-68.44-80.62
Upgrade
EBITDA Margin
-3392.62%-1694.37%-408.77%-775.70%-
Upgrade
Depreciation & Amortization
2.172.412.522.382.05
Upgrade
EBIT
-97.34-109.87-80.85-70.82-82.68
Upgrade
EBIT Margin
-3470.05%-1732.43%-421.89%-802.66%-
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).